University of Texas, Southwestern Medical Center
Welcome,         Profile    Billing    Logout  
 16 Trials 
89 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Euhus, David M
PROMISE, NCT02694809: The Study: Duavee in Women With DCIS

Completed
2
142
US
Conjugated Estrogens/Bazedoxifene, Laboratory Biomarker Analysis, Pharmacological Study, Placebo, placebo therapy, PLCB, sham therapy, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
Northwestern University, National Cancer Institute (NCI), Pfizer, University of Chicago - Department for Cancer Research, University of California, San Francisco
Ductal Breast Carcinoma In Situ, Postmenopausal
06/24
06/24
Boughey, Judy
A011202, NCT01901094: Comparison of Axillary Lymph Node Dissection with Axillary Radiation for Patients with Node-Positive Breast Cancer Treated with Chemotherapy

Active, not recruiting
3
2012
Canada, US
Axillary Lymph Node Dissection (ALND), Nodal Radiation Therapy, Axillary Radiation Therapy
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Canadian Cancer Trials Group
Stage II Breast Cancer, Stage IIIA Breast Cancer
01/26
01/26
NCT00881361: Surgery to Remove the Sentinel Lymph Node and Axillary Lymph Nodes After Chemotherapy in Treating Women With Stage II, Stage IIIA, or Stage IIIB Breast Cancer

Completed
2
756
US
systemic chemotherapy, axillary lymph node dissection, neoadjuvant therapy, sentinel lymph node biopsy, therapeutic conventional surgery, ultrasound imaging
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Breast Cancer
11/12
04/23
NCT01556243: Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer

Completed
2
270
US
therapeutic conventional surgery, whole breast irradiation
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Breast Cancer
06/22
04/23
I-SPY 2, NCT01042379: I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Hourglass Jan 2023 - Dec 2023 : From P2 I-SPY 2 trial for invasive breast cancer
Checkmark Presentation of data from I-SPY trial for HR+/HER2- and TNBC breast cancer at SABCS 2022
Dec 2022 - Dec 2022: Presentation of data from I-SPY trial for HR+/HER2- and TNBC breast cancer at SABCS 2022
Checkmark Data from trial evaluating T-DM1+pertuzumab in the adjuvant setting
Nov 2018 - Nov 2018: Data from trial evaluating T-DM1+pertuzumab in the adjuvant setting
More
Recruiting
2
5000
US
Standard Therapy, Paclitaxel (Taxol); Doxorubicin (Adriamycin), AMG 386 with or without Trastuzumab, AMG 386 (Trebananib); (Trastuzumab) Herceptin, AMG 479 (Ganitumab) plus Metformin, Ganitumab, MK-2206 with or without Trastuzumab, (Trastuzumab) Herceptin, AMG 386 and Trastuzumab, AMG 386 (Trebananib); Trastuzumab (Herceptin), T-DM1 and Pertuzumab, T-DM1 (Trastuzumab emtansine); Pertuzumab (Perjeta), Pertuzumab and Trastuzumab, Pertuzumab (Perjeta); Trastuzumab (Herceptin), Ganetespib, ABT-888, Veliparib, Neratinib, PLX3397, Pembrolizumab - 4 cycle, Talazoparib plus Irinotecan, Patritumab and Trastuzumab, Pembrolizumab - 8 cycle, SGN-LIV1A, Durvalumab plus Olaparib, SD-101 + Pembrolizumab, Tucatinib plus trastuzumab and pertuzumab, Cemiplimab, Cemiplimab plus REGN3767, Trilaciclib with or without trastuzumab + pertuzumab, Trilaciclib (G1T28); Pertuzumab (Perjeta); Trastuzumab (Herceptin), SYD985 ([vic-]trastuzumab duocarmazine), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab, Oral Paclitaxel + Encequidar (Oraxol); Dostarlimab (TSR-042); Trastuzumab (Herceptin), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab, Amcenestrant, SAR439859, Amcenestrant + Abemaciclib, Amcenestrant (SAR439859), Abemaciclib (Verzenio), Amcenestrant + Letrozole, Amcenestrant (SAR439859), Letrozole (Femara), ARX788, ARX788 + Cemiplimab, VV1 + Cemiplimab, VOYAGER V1™, VSV-IFNβ-NIS, Datopotamab deruxtecan, Dato-DXd, Datopotamab deruxtecan + Durvalumab, Zanidatamab, Lasofoxifene, Z-endoxifen, ARV-471, ARV-471 + Letrozole, ARV-471 + Abemaciclib, Endoxifen + Abemaciclib, Rilvegostomig + TDXd, Dan222 + Niraparib, Sarilumab + Cemiplimab + Paclitaxel
QuantumLeap Healthcare Collaborative
Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
12/30
12/31
BEAUTY, NCT02022202: Breast Cancer Genome Guided Therapy Study

Active, not recruiting
N/A
140
US
Mayo Clinic
Invasive Breast Cancer
05/14
12/32
NCT05547347: Safety, Ultrasound Conspicuity, and Migration of Twinkling Markers in Patients with Locally Advanced Breast Cancer

Enrolling by invitation
N/A
15
US
Magnetic Resonance Imaging, Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Mammogram, Ultrasound, Ultrasound-Guided Biopsy, Ultrasound Guided Biopsy, Twinkle marker
Mayo Clinic, National Cancer Institute (NCI)
Anatomic Stage III Breast Cancer AJCC V8, Locally Advanced Breast Carcinoma, Resectable Breast Carcinoma
12/25
12/25
NCT02945579: Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy

Recruiting
N/A
120
US
External Beam Radiation Therapy, Definitive Radiation Therapy, EBRT, External Beam Radiotherapy, External Beam RT, external radiation, External Radiation Therapy, external-beam radiation, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Whole Breast Irradiation
M.D. Anderson Cancer Center, National Cancer Institute (NCI), Artidis
Estrogen Receptor Negative, HER2 Positive Breast Carcinoma, HER2/Neu Negative, Invasive Breast Carcinoma, Progesterone Receptor Negative, Stage I Breast Cancer AJCC V7, Stage IA Breast Cancer AJCC V7, Stage IB Breast Cancer AJCC V7, Stage II Breast Cancer AJCC V6 and V7, Stage IIA Breast Cancer AJCC V6 and V7, Stage IIB Breast Cancer AJCC V6 and V7, Triple-Negative Breast Carcinoma
01/26
01/26
BEAUTY, NCT05703399: Long Term Followup of Patients Enrolled in MC1137, Study

Recruiting
N/A
140
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Questionnaire Administration
Mayo Clinic, National Cancer Institute (NCI)
Breast Carcinoma
12/32
12/33
NCT04703244: Development of Patient Derived Xenografts (PDX) in Patients With Breast Cancer

Recruiting
N/A
100
US
chemotherapy or endocrine therapy for breast cancer
Mayo Clinic
Breast Cancer, Residual
01/41
01/42
Cost, Carrye
NCT04901702 / 2021-003570-31: Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

Active, not recruiting
1/2
46
Canada, US
Onivyde, Nanoliposomal irinotecan, Talazoparib, BMN 673, Talzenna, Temozolomide, Temodar, Temodal
St. Jude Children's Research Hospital, Pfizer, Ipsen
Recurrent Solid Tumor, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Solid Neoplasm, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Recurrent Wilms Tumor, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Malignant Germ Cell Tumor, Refractory Malignant Solid Neoplasm, Refractory Neuroblastoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma
12/25
12/25
NCT03900793: Losartan + Sunitinib in Treatment of Osteosarcoma

Recruiting
1
41
US
Losartan, Sunitinib, Sunitinib Malate
University of Colorado, Denver, Cancer League of Colorado, Colorado State University, Swim Across America
Osteosarcoma
08/26
02/27
Badgett, Tom
NCT02205762 / 2011-001699-20: LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis

Recruiting
2/3
1400
US
Prednisone, Vinblastine, Velban®, Vincaleukoblastine Sulfate, mercaptopurine, -Purinethol®, -6-MP, INDOMETHACIN, Methotrexate, Cytosine Arabinoside, Cytarabine, Ara-C, 2-chlorodeoxyadenosine, 2-CdA, Cladribin®, Leustatin®, hematopoietic stem cell transplantation (RIC-HSCT), Intravenous immunoglobulin, IVIG
North American Consortium for Histiocytosis, Histiocyte Society
Langerhans Cell Histiocytosis
07/25
07/25
NMTT, NCT02679144: Neuroblastoma Maintenance Therapy Trial

Recruiting
2
441
Canada, US
Difluoromethylornithine (DFMO), eflornithine
Giselle Sholler, Beat NB Cancer Foundation, Team Parker for Life
Neuroblastoma
02/28
02/33
NCT04696029: DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma

Recruiting
2
118
US
Difluoromethylornithine, Eflornithine, DFMO
Giselle Sholler
Medulloblastoma
03/28
03/29
NCT02318589: Phase I of Eribulin and Oral Irinotecan for Relapsed or Refractory Solid Tumors

Recruiting
1
18
US
Irinotecan + Eribulin
Tom Badgett
Solid Tumor
06/19
06/20
Zhang, Tian
PDIGREE, NCT03793166: Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The Study

Checkmark Initiated in combination with nivolumab and ipilimumab for 1L RCC
Jan 2019 - Jan 2019: Initiated in combination with nivolumab and ipilimumab for 1L RCC
Active, not recruiting
3
1175
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Scan, Bone Scintigraphy, Cabozantinib, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS 734016, BMS-734016, BMS734016, Ipilimumab Biosimilar CS1002, MDX 010, MDX-010, MDX-CTLA4, MDX010, Yervoy, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
National Cancer Institute (NCI)
Clear Cell Renal Cell Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Lymph Nodes, Metastatic Malignant Neoplasm in the Soft Tissues, Metastatic Malignant Neoplasm in the Viscera, Rhabdoid Tumor of the Kidney, Sarcomatoid Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
09/25
09/25
CYCLONE 3, NCT05288166: A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

Active, not recruiting
3
900
Europe, Canada, Japan, US, RoW
Abemaciclib, LY2835219, Abiraterone, Prednisone or Prednisolone, Placebo for Abemaciclib
Eli Lilly and Company
Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6
02/24
10/27
NCT05987241: Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder for Bladder Cancer Treatment, MODERN Study

Recruiting
2/3
1190
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, cfDNA or ctDNA Measurement, Cell-Free DNA/Circulating Tumor DNA Measurement, cfDNA/ctdDNA Measurement, cfDNA/ctDNA, cfDNA/ctDNA Measurement, Circulating Cell-Free DNA/Circulating Tumor-Derived DNA Measurement, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Relatlimab, BMS 986016, BMS-986016, BMS986016, Immunoglobulin G4, Anti-(human Lymphocyte Activation Gene-3 Protein) (Human Heavy Chain), Disulfide with Human Light Chain, Dimer
National Cancer Institute (NCI)
Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma AJCC v6 and v7, Stage III Bladder Urothelial Carcinoma AJCC v6 and v7, Stage IV Bladder Urothelial Carcinoma AJCC v7
04/26
04/26
STARTAR, NCT03311555: A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy

Completed
2
39
US
Apalutamide, ARN-509, JNJ-56021927, Androgen deprivation, Salvage radiation therapy, Docetaxel
Andrew J. Armstrong, MD
Prostate Cancer
12/22
12/22
EV-ECLIPSE, NCT05239624: Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer

Recruiting
2
23
US
Enfortumab vedotin, Pembrolizumab
Memorial Sloan Kettering Cancer Center, Astellas Pharma US, Inc., Seagen Inc., Merck Sharp & Dohme LLC
Urothelial Carcinoma
06/26
06/26
OPTIC RCC, NCT05361720: Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, Study

Recruiting
2
54
US
Cabozantinib, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy, Nivolumab, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo
Vanderbilt-Ingram Cancer Center, National Cancer Institute (NCI), United States Department of Defense
Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
07/25
07/26
Seq-Cabo, NCT05931393: Sequential Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC)

Recruiting
2
18
US
Cabozantinib 80 MG
University of Texas Southwestern Medical Center, Exelixis
RCC, Renal Cell Carcinoma
09/25
12/27
NCI-2022-02837, NCT05282459: Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation

Active, not recruiting
1/2
17
US
Enasidenib mesylat dose escalation, (Idhifa, AG 221)
Stanford University, Celgene Corporation
Leukemia, Leukemia, Myeloid, Monocytic Leukemia
01/25
04/25
LIBRETTO-001, NCT03157128 / 2017-000800-59: A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer

Hourglass Jan 2022 - Dec 2022 : Submission for lung cancer
Hourglass Apr 2022 - Dec 2022 : Approval in China for RET+NSCLC, medullary thyroid cancer and thyroid cancer
Checkmark From LIBRETTO-001 trial in RET fusion-positive NSCLC
Aug 2020 - Aug 2020: From LIBRETTO-001 trial in RET fusion-positive NSCLC
Checkmark Granted for advanced RET fusion+ve 2L thyroid cancer [LIBRETTO-001]
More
Active, not recruiting
1/2
856
Europe, Canada, Japan, US, RoW
LOXO-292, Selpercatinib, LY3527723
Loxo Oncology, Inc., Eli Lilly and Company
Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Any Solid Tumor
02/25
02/26
STAR-EV, NCT06394570: Enfortumab Vedotin and Stereotactic Radiation for Localized, Cisplatin Ineligible Muscle Invasive Bladder Cancer

Recruiting
1/2
19
US
Enfortumab vedotin, PADCEV
University of Texas Southwestern Medical Center, Astellas Pharma Inc
Bladder Cancer
07/26
07/27
PRESERVE-006, NCT05682443: ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC

Recruiting
1/2
144
US
ONC-392, A humanized anti-CTLA4 IgG1 monoclonal antibody, Gotistobart, lutetium Lu 177 vipivotide tetraxetan, IV infusion, Q6W for up to 6 doses., Pluvicto
OncoC4, Inc., Prostate Cancer Clinical Trials Consortium
Metastatic Castration-resistant Prostate Cancer
06/26
06/27
NCT05892718: A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors

Recruiting
1
60
US, RoW
HCB101, SIRPα-Fc fusion protein
FBD Biologics Limited
Advanced Solid Tumor, Refractory Non-Hodgkin Lymphoma
05/25
11/25
NCT02978118: Exploring Relevant Immune-based Biomarkers and Circulating Tumor Cells During Treatment With Immunotherapy in Genitourinary Malignancies (CTC Immune Based Biomarkers)

Recruiting
N/A
300
US
Immune cell and CTC detection procedures
Duke University, University of Wisconsin, Madison
Carcinoma, Renal Cell, Carcinoma, Urothelial
10/28
10/28
NCT06479343: Efficacy and Safety of the Liquid Embolic System (Tonbridge) for Endovascular Treatment of Cerebrovascular Malformations

Recruiting
N/A
170
RoW
Liquid Embolic System (Tonbridge), Onyx Liquid Embolic System (Medtronic)
Zhuhai Tonbridge Medical Tech. Co., Ltd.
Intracranial Arteriovenous Malformations
10/25
10/26
NCT05755516: Efficacy and Safety of the Self-expanding Intracranial Stent (Tonbridge) for Endovascular Treatment of Intracranial Aneurysms

Active, not recruiting
N/A
204
RoW
Self-expanding Intracranial Stent (Tonbridge), LVIS and LVIS Jr. (MicroVention)
Zhuhai Tonbridge Medical Tech. Co., Ltd.
Intracranial Aneurysm
10/24
04/25
ODYSSEY RCC, NCT04919122: Outcomes Database to prospectivelY aSSEss the Changing TherapY Landscape in Renal Cell Carcinoma

Recruiting
N/A
800
US
Duke University, Duke Clinical Research Institute, Bristol-Myers Squibb, Exelixis, Merck Sharp & Dohme LLC, Pfizer
Metastatic Renal Cell Carcinoma
07/26
07/26
IRONMAN, NCT03151629: International Registry for Men With Advanced Prostate Cancer

Recruiting
N/A
5000
Europe, Canada, US, RoW
Standard of Care
Prostate Cancer Clinical Trials Consortium
Prostate Cancer
01/31
01/32
Bernstein, Caryn
NCT06400004: Lumason® Infusion vs. Bolus Administrations

Not yet recruiting
3
106
US
Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Injection Powder for Suspension [LUMASON], Bolus Administration, Lumason, Infusion Administration
Bracco Diagnostics, Inc
Heart Diseases
07/24
12/24
CLASP IID, NCT03706833: Edwards PASCAL /IIF Pivotal Clinical Trial

Recruiting
N/A
1247
Europe, Canada, US
Edwards PASCAL System, Transcatheter Mitral Valve repair (TMVr), Abbott Mitraclip System
Edwards Lifesciences
Degenerative Mitral Valve Disease, Mitral Regurgitation, Mitral Insufficiency, Functional Mitral Regurgitation
01/25
04/30
NCT04905017: Trisol System EFS Study

Recruiting
N/A
15
US
Transcatheter Tricuspid Valve Replacement
Trisol Medical
Tricuspid Regurgitation
01/25
07/27
ENGULF, NCT05597891: Endovascular Engineering Study

Recruiting
N/A
181
US
Hēlo PE Thombectomy System
Endovascular Engineering
Pulmonary Embolism
08/25
09/25
ACES-EMB, NCT06414603: A Comparative Effectiveness Study in Heart Transplant Patients of Rejection Surveillance With Cell-free DNA Versus Endomyocardial Biopsy

Recruiting
N/A
250
US
The Prospera™ Test
Natera, Inc.
Heart Transplant Failure and Rejection
12/24
12/25
CHAMPIONSHIP, NCT06410313: First in Human Study to Assess Safety and Efficacy of the ChampioNIR™ Drug Eluting Peripheral Stent in the Treatment of Patients with Superficial Femoral Artery Disease And/or Proximal Popliteal Artery Disease

Recruiting
N/A
30
US, RoW
ChampioNIR Ridaforolimus Eluting Peripheral Stent System
Medinol Ltd.
Superficial Femoral Artery Stenosis, Popliteal Artery Stenosis
08/25
02/28
AHEAD, NCT03813524: Cardiovalve Transfemoral Mitral Valve System

Terminated
N/A
1
US
Cardiovalve Transfemoral Mitral Valve
Boston Biomedical Associates, Cardiovalve Ltd., Cardiovascular Research Foundation, New York
Mitral Regurgitation
03/20
03/20
LeAAPS, NCT05478304: Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial

Recruiting
N/A
6500
Europe, Canada, US
AtriClip LAA Exclusion System
AtriCure, Inc., Population Health Research Institute
Ischemic Stroke, Systemic Embolism
12/31
04/32
Barata, Pedro
PROBE, NCT04510597: Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the Trial

Recruiting
3
364
US
Cytoreductive Nephrectomy, Active Comparator
SWOG Cancer Research Network, National Cancer Institute (NCI)
Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8
07/33
07/33
NCT06312670: Combining EPI-7386 with Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer

Active, not recruiting
2
13
US
EPI-7386, Enzalutamide, Androgen Deprivation Therapy (ADT)
Pedro Barata, MD, MSc, ESSA Pharma Inc.
Metastatic Hormone-sensitive Prostate Cancer (mHSPC), Prostate Cancer, Prostate Adenocarcinoma
03/26
03/26
NCT06738303: Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer

Not yet recruiting
2
44
US
Cabazitaxel and carboplatin, Lu-PSMA-617, Pluvicto
Case Comprehensive Cancer Center
Metastatic Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
12/26
12/26
CASCARA, NCT03934840: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone

Active, not recruiting
2
22
US
Cabazitaxel, Carboplatin, Abiraterone, Prednisone
Masonic Cancer Center, University of Minnesota
Prostate Cancer
06/23
05/25
OPTIC RCC, NCT05361720: Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, Study

Recruiting
2
54
US
Cabozantinib, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy, Nivolumab, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo
Vanderbilt-Ingram Cancer Center, National Cancer Institute (NCI), United States Department of Defense
Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
07/25
07/26
NCT05588609: Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers

Active, not recruiting
2
90
US
Afatinib Oral Tablet, GILOTRIF®, GIOTRIF®, Enzalutamide Pill, XTANDI®, Abiraterone acetate tablets, ZYTIGA®, MCLA-128, Zenocutuzumab
Merus N.V.
NSCLC Harboring NRG1 Fusion, Metastatic Castration-resistant Prostate Cancer
10/25
03/26
NCT04267120: Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial)

Active, not recruiting
2
11
US
Lenvatinib, Lenvima, Lenvanix, Pembrolizumab, Keytruda, MK-3475, Research blood collection
Washington University School of Medicine, Merck Sharp & Dohme LLC
Renal Cell Carcinoma
07/24
12/25
PAPMET2, NCT05411081: Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, Trial

Recruiting
2
200
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG 7446, RG-7446, RG7446, RO 5541267, RO-5541267, RO5541267, Tecentriq, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Scan, Bone Scintigraphy, Cabozantinib S-malate, BMS-907351, Cabometyx, Cometriq, XL 184, XL-184, XL184, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI
National Cancer Institute (NCI)
Metastatic Papillary Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8
07/27
07/27
SAMURAI, NCT05327686: Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, Study

Recruiting
2
240
US
Avelumab, Bavencio, MSB-0010718C, MSB0010718C, Axitinib, AG-013736, AG013736, Inlyta, Cabozantinib, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy, Lenvatinib, E7080, ER-203492-00, Multi-Kinase Inhibitor E7080, Nivolumab, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Stereotactic Ablative Radiotherapy, SABER, SABR, SBRT, Stereotactic Ablative Radiation Therapy
NRG Oncology, National Cancer Institute (NCI)
Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Unresectable Renal Cell Carcinoma
06/28
06/32
CombTMS, NCT06500533: Combining RTMS and TDCS in Depression: an Exploratory Clinical Trial

Recruiting
N/A
40
Europe
rTMS combined with tDCS
Regionspsykiatrien Gødstrup, Regionspsykiatrien Randers
Major Depression, Treatment Resistant Depression
12/27
12/27
IRONMAN, NCT03151629: International Registry for Men With Advanced Prostate Cancer

Recruiting
N/A
5000
Europe, Canada, US, RoW
Standard of Care
Prostate Cancer Clinical Trials Consortium
Prostate Cancer
01/31
01/32
Access, Vanderbilt-Ingram Service for Timely
NCT06016855: Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors

Recruiting
4
6
US
Tumor Debulking, Lutetium Lu 177 Dotatate, Computed Tomography, Magnetic Resonance Imaging, Copper Cu 64 Dotatate, Positron Emission Tomography
Vanderbilt-Ingram Cancer Center
Digestive System Neuroendocrine Tumor G1, Digestive System Neuroendocrine Tumor G2, Metastatic Digestive System Neuroendocrine Neoplasm, Metastatic Malignant Neoplasm in the Liver, Pancreatic Neuroendocrine Tumor G1, Pancreatic Neuroendocrine Tumor G2
05/27
05/28
FROSTBITE-3, NCT06105801: EBUS-TBNA vs Transbronchial Mediastinal Cryobiopsy for Adequacy of Next Generation Sequencing

Recruiting
3
250
US
Endobronchial ultrasound with transbronchial needle aspiration, Bronchoscopy, Cryobiopsy
Vanderbilt-Ingram Cancer Center
Lung Cancer
10/27
10/28
NCT03694249: Ifetroban in Treating Patients With Malignant Solid Tumors at High Risk of Metastatic Recurrence

Active, not recruiting
2
30
US
Ifetroban Sodium, Placebo
Vanderbilt-Ingram Cancer Center, Cumberland Pharmaceuticals
Malignant Solid Tumor
04/25
04/26
NCT06140407: Pembrolizumab After Radiation Therapy and Chemotherapy in Limited Stage Small Cell Lung Cancer

Recruiting
2
20
US
Cisplatin, Carboplatin, Etoposide, Pembrolizumab, Computed Tomography, Positron Emission Tomography, Magnetic Resonance Imaging, Biospecimen Collection, Radiation Therapy
Vanderbilt-Ingram Cancer Center, Merck Sharp & Dohme LLC
Limited Stage Lung Small Cell Carcinoma, Stage I Lung Cancer, Stage II Lung Cancer, Stage III Lung Cancer
05/28
05/29
NCT04327999: Effect of Artificial Tears on Radioiodine Levels in the Nasolacrimal Duct System

Terminated
2
9
US
Artificial Tears
Vanderbilt-Ingram Cancer Center
Thyroid Carcinoma, Radioactive Iodine Level
09/23
09/23
OPTIC RCC, NCT05361720: Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, Study

Recruiting
2
54
US
Cabozantinib, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy, Nivolumab, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo
Vanderbilt-Ingram Cancer Center, National Cancer Institute (NCI), United States Department of Defense
Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
07/25
07/26
NCT05660421: Itacitinib for the Treatment Steroid Refractory Immune Related Adverse Events Arising From Immune Checkpoint Inhibitors

Withdrawn
2
25
NA
Itacitinib, Corticosteroid, Endoscopic Procedure, Skin biopsy, Biospecimen Collection
Douglas Johnson, Incyte Corporation
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
09/26
04/27
NCT04506008: Hypofractionated Radiotherapy Followed by Surgical Resection in the Treatment of Soft Tissue Sarcomas

Recruiting
2
40
US
Ultra-Hypo-fractionation Radiotherapy, Resection, Questionnaire Administration, Moderately-Hypo-fractionation Radiotherapy
Vanderbilt-Ingram Cancer Center
Soft Tissue Sarcomas
06/26
06/27
INSIGHT, NCT05693766: Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort

Recruiting
2
64
US
Capecitabine, Endocrine-therapy, MammoPrint ® and BluePrint assays
Sonya Reid, Agendia, Susan G. Komen Breast Cancer Foundation
Invasive Mammary Carcinoma, Metastatic Breast Cancer
08/27
08/37
NCT05799144: pBI-11 & TA-HPV (With Pembrolizumab as Treatment for Patients w/Advanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal Cancer

Recruiting
2
54
US
DNA Vaccine, Human Papillomavirus Tumor Antigen Vaccine, Pembrolizumab, Computed Tomography (CT), Magnetic Resonance Imaging (MRI), Magnetic Resonance Imaging, Biopsy
Michael K. Gibson
Metastatic Oropharyngeal Carcinoma, Recurrent Oropharyngeal Carcinoma
09/27
09/28
NCT05770531: Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy

Suspended
2
120
US
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Sacituzumab Govitecan
Vanderbilt-Ingram Cancer Center, National Cancer Institute (NCI)
Metastatic HER2-Negative Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma
10/27
10/28
NCT05799079: Decitabine and Cedazuridine in Combination With Venetoclax for the Treatment of Patients Who Have Relapsed Acute Myeloid Leukemia After Donor Stem Cell Transplant

Recruiting
2
51
US
Venetoclax, Decitabine, Cedazuridine, Bone Marrow Aspiration and Biopsy, Biospecimen Collection
Sanjay Mohan, National Comprehensive Cancer Network, Taiho Oncology, Inc.
Recurrent Acute Myeloid Leukemia
03/28
03/29
NCT05764395: Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors

Suspended
2
29
US
Rigosertib, Pembrolizumab, Magnetic Resonance Imaging, Biospecimen Collection, Biopsy
Vanderbilt-Ingram Cancer Center
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma, Refractory Melanoma, Unresectable Melanoma
05/28
05/29
VICC-NCBRE23172, NCT05919108: Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers

Recruiting
2
30
US
Endocrine Therapy, Biopsy of breast, Neratinib, Biospecimen Collection, Mammogram, Magnetic Resonance Imaging, Breast Surgery, Ultrasound
Vanderbilt-Ingram Cancer Center, National Cancer Institute (NCI), Puma Biotechnology, Inc.
Anatomic Stage I Breast Cancer, Anatomic Stage II Breast Cancer, Anatomic Stage III Breast Cancer, Invasive Breast Lobular Carcinoma
04/30
04/31
NCT05156060: Gabapentin & Ketamine for Prevention/Treatment of Acute/Chronic Pain in Locally Advanced Head and Neck Cancer

Recruiting
1/2
64
US
Gabapentin, Neurontin, Ketamine, Ketalar
Natalie Lockney
Head and Neck Cancer, Locally Advanced Head and Neck Carcinoma
12/25
12/26
SiCARIO, NCT05501665: Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer

Recruiting
1/2
25
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized Tomography, CT, CT Scan, tomography, Fludeoxyglucose F-18, 18FDG, FDG, Fludeoxyglucose (18F), fludeoxyglucose F 18, Fludeoxyglucose F18, Fluorine-18 2-Fluoro-2-deoxy-D-Glucose, Fluorodeoxyglucose F18, Nab-paclitaxel, ABI 007, ABI-007, Abraxane, Albumin-bound Paclitaxel, Albumin-Stabilized Nanoparticle Paclitaxel, Nanoparticle Albumin-bound Paclitaxel, Nanoparticle Paclitaxel, Paclitaxel Albumin, paclitaxel albumin-stabilized nanoparticle formulation, Protein-bound Paclitaxel, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Pemetrexed, MTA, Multitargeted Antifolate, Pemfexy, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, Radiation Therapy, Cancer Radiotherapy, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, [18-F] (fluoropropyl)-L-glutamate (FSPG) PET scan, Ipilimumab, Nivolumab, Cemiplimab, Atezolizumab
Vanderbilt-Ingram Cancer Center, National Cancer Institute (NCI), Varian Medical Systems
Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage III Lung Cancer
02/26
02/27
TESSERACT, NCT06110572: Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation

Recruiting
1/2
18
US
Carboplatin, Atezolizumab, Etoposide, Total Body Irradiation, Hypofractionated Radiation Therapy, Magnetic Resonance Imaging
Vanderbilt-Ingram Cancer Center, Genentech, Inc.
Extensive Stage Lung Small Cell Carcinoma, Stage IV Lung Cancer
06/27
06/28
NCT06399640: Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia

Recruiting
1
60
US
Eltanexor, KPT-8602, Venetoclax, Bone Marrow Aspiration and Biopsy, Biospecimen Collection
Vanderbilt-Ingram Cancer Center, Karyopharm Therapeutics Inc, National Cancer Institute (NCI)
Relapsed Myelodysplastic Syndrome, Refractory Myelodysplastic Syndrome, Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
12/25
12/26
PANTHEoN, NCT04892875: A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers

Withdrawn
1
24
NA
Zimberelimab, AB122, Etrumadenant, AB928, Cisplatin, Radiation
Jennifer Choe, Arcus Biosciences, Inc.
Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck, Oral Cavity Squamous Cell Carcinoma, Oral Cavity Cancer, Oropharynx Cancer, Oropharynx Squamous Cell Carcinoma, Larynx Cancer, Pharynx Cancer, Hypopharynx Cancer, Hypopharynx Squamous Cell Carcinoma
12/25
12/26
NCT05996432: Image-Based, In-Vivo Assessment of Tumor Hypoxia to Guide Hypoxia-Driven Adaptive Radiation Therapy

Recruiting
1
48
US
Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), 18F-fluoromisonidazole
Vanderbilt-Ingram Cancer Center, National Institutes of Health (NIH)
Head and Neck Squamous Cell Carcinoma, Brain Metastases
11/26
05/29
NCT05747625: (89Zr Panitumumab) With PET/CT for Diagnosing Metastases in Patients With Head and Neck Squamous Cell Carcinoma

Recruiting
1
60
US
Panitumumab, Zirconium Zr 89 Panitumumab, Positron Emission Tomography, Computed Tomography, Electronic Health Record Review
Michael Topf
Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck
02/27
03/30
NCT05945875: Evaluating the Use of Dual Imaging Techniques for Detection of Disease in Patients with Head and Neck Cancer

Recruiting
1
40
US
Panitumumab-IRDye800, Indium In 111 Panitumumab, Single Photon Emission Computed Tomography, Computed Tomography, Resection, Fluorescence Imaging
Vanderbilt-Ingram Cancer Center, National Cancer Institute (NCI)
Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
12/27
12/28
NCT05901545: Evaluating 111In Panitumumab for Nodal Staging in Head and Neck Cancer

Recruiting
1
30
US
Panitumumab, Indium In 111 Panitumumab, Single Photon Emission Computed Tomography, Computed Tomography, Surgical Procedure, Imaging agent, Intraoperative Imaging, Near Infrared Imaging, Electrocardiography, Biospecimen Collection
Vanderbilt-Ingram Cancer Center, American Cancer Society, Inc.
Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
11/28
11/29
CHIVE, NCT06701214: The Clonal Hematopoiesis & Inflammation in Vasculature Registry and Biorepository

Recruiting
N/A
800
US
Blood collection, Saliva collection, Bone marrow collection
Vanderbilt-Ingram Cancer Center
Clonal Hematopoiesis
11/30
11/31
CAUSAL, NCT06482957: Cohort to Augment the Understanding of Sarcoma Survivorship Across the Lifespan

Recruiting
N/A
2100
US
Surveys, Blood Collection, Saliva Collection, Urine Collection, Stool Collection, Tissue collection, Physical Activity Monitoring
Vanderbilt-Ingram Cancer Center, National Cancer Institute (NCI)
Sarcoma
04/28
04/29
NCT04803084: Multiparametric MRI as a Non-Invasive Biomarker of the Tumor Microenviroment

Suspended
N/A
10
US
Tempus assay, Advanced pathology 1, Advanced pathology 2
Laura Kennedy, National Cancer Institute (NCI)
Breast Cancer, Triple-negative Breast Cancer
08/24
08/25
NCT05135260: Virtual Reality on Pain, Stress, and Affect in the Infusion Clinic

Completed
N/A
99
US
Virtual reality therapy, Questionnaires, Measure heart rate, Cyber sickness measurement
Cody Stansel
Cancer, Chemotherapy
12/23
12/23
NCT05108805: Chimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient Setting

Active, not recruiting
N/A
25
US
Telemedicine Visit, Vital sign measurements, Out-Patient Clinic Visit, Blood pressure and pulse oximeter
Vanderbilt-Ingram Cancer Center, Kite, A Gilead Company
Large B-cell Lymphoma, Diffuse Large B-cell Lymphoma
02/24
12/24
NCT06593106: Cryodevitalization for the Treatment of Early Stage Lung Cancer, CRYSTAL Trial

Recruiting
N/A
30
US
Cryosurgery, Robotic Bronchoscopy, Bronchoscopy with Biopsy, Resection, Chest Radiography, Computed Tomography, Biospecimen Collection, Electronic Health Record Review
Vanderbilt-Ingram Cancer Center, National Cancer Institute (NCI), Swim Across America
Stage I Lung Cancer, Stage II Lung Cancer
12/25
08/26
NCT06638398: Biomarker Platform (Virtual Nodule Clinic) for the Management of Indeterminate Pulmonary Nodules

Recruiting
N/A
400
US
Computed Tomography, Diagnostic Procedure, Best Practice, Electronic Health Record Review
Vanderbilt-Ingram Cancer Center, National Cancer Institute (NCI)
Lung Neoplasm
12/26
12/27
NCT04461171: Enhanced Recovery After Surgery in Extremity Sarcoma

Recruiting
N/A
120
US
Enhanced Recovery After Surgery
Joshua Lawrenz
Sarcoma
12/25
06/26
NCT01205815: Storage and Research Use of Human Bio-specimens From Melanoma Patients and Clinical Testing for Assignment of Treatment

Recruiting
N/A
3000
US
Tissue and blood collection
Vanderbilt-Ingram Cancer Center
Melanoma
01/25
08/25
NCT06074133: A Combined Biomarker Model for Risk Stratification of Indeterminate Pulmonary Nodules

Recruiting
N/A
100
US
Blood collection, Chest Computed Tomography
Vanderbilt-Ingram Cancer Center, National Cancer Institute (NCI)
Pulmonary Nodule
03/27
03/29
RIVERBOAT, NCT03932786: Studying Health Outcomes After Treatment in Patients With Retinoblastoma

Recruiting
N/A
900
Canada, US
Biospecimen collection, Vision assessment, Questionnaire administration, Quality of life assessment, Laboratory Biomarker Analysis
Vanderbilt-Ingram Cancer Center, National Cancer Institute (NCI)
Retinoblastoma, Cancer Survivor, Biological Sibling, Intraocular Retinoblastoma, Unilateral Retinoblastoma
01/30
01/31
ENCORE, NCT04758338: Enhancing Cancer Care Of Rural Dwellers

Active, not recruiting
N/A
814
US
VUMC telehealth services, Interview, Educational materials
Debra Friedman, National Cancer Institute (NCI)
Cancer
12/30
12/31
GAP, NCT05734430: Genetics of Appendix Cancer Study

Recruiting
N/A
700
US
Genetic profiling, Retrospective tissue procurement
Andreana Holowatyj, PhD, MSCI
Appendix Cancer, Appendiceal Cancer, Appendiceal Neoplasms, Appendiceal Mucinous Neoplasm, Appendiceal Adenocarcinoma, Appendiceal Carcinoid Tumor, Appendiceal Neoplasm Malignant Secondary, Appendix Adenocarcinoma, Appendix Mucinous Neoplasm, Appendix Tumor, Appendix Cancer Metastatic, Appendix NET, Low-Grade Appendix Mucinous Neoplasm, High Grade Appendix Mucinous Neoplasm, High Grade Appendix Mucinous Adenocarcinoma
11/32
11/34
PREFACE, NCT05239338: Preserving Fertility After Colorectal Cancer Study

Recruiting
N/A
1000
US
Andreana Holowatyj, PhD, MSCI
Colorectal Cancer
12/36
12/37

Download Options